A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Effortless Measurement of All Four NADs and Glutathione for Laboratories

About

In response to the escalating demand from clinicians and researchers for precise and fast NAD measurement, NADMED unveils an innovative technology designed for extracting and measuring all four NADs and two glutathiones. The method is founded on colorimetric quantification, applicable to blood, tissue, or cells.

Distinguishing Feature of NADMED

The distinguishing feature of the NADMED method lies in its ability to measure metabolites individually, setting it apart from other methods and delivering exceptional accuracy comparable to mass spectrometry. Based on transparent scientific research from the University of Helsinki, NADMED’s technology presents fresh business opportunities for laboratories.

NADMED’s laboratory technology is available in kits, with the first EU IVDD compliant (CE-marked) kits for blood NAD+ and NADH already for sale. Kits for the remaining metabolites are slated for production by the year’s end.

Measuring NAD Metabolites and Glutathione

Measuring NAD metabolites and glutathione has long been hindered by the absence of a rapid and reliable method, impeding both research and the development of clinical applications for these REDOX molecules. NADMED’s technology presents a fast, scalable, and cost-effective solution. Unlike mass spectrometer analysis, which may take days, NADMED analysis yields results within hours. Moreover, NADMED makes this analysis accessible for laboratories without mass spectrometry, at a fraction of the total cost.

Jari Närhi, CEO of NADMED

“We believe that the NADMED method will advance science and medical practice by enabling larger and quicker clinical trials and in due course, diagnostics. NAD measuring should be seen as a first-line diagnostic tool in the future to fight for example degenerative diseases and metabolic disorders.”

For more information, please visit www.nadmed.com.

SourceNADMED
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.
"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."
The relationship between pharmaceutical companies and CDMOs is fundamentally collaborative, fostering an environment of innovation. By partnering with a CDMO, pharmaceutical firms can access a wide array of technologies and expertise that might otherwise be beyond their reach.
Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.

By using this website you agree to accept Medical Device News Magazine Privacy Policy